Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVO NASDAQ:FNCH NASDAQ:PDSB NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$3.57-4.5%$3.36$2.13▼$13.13$48.29M-0.6816.89 million shs250,204 shsFNCHFinch Therapeutics Group$7.30$7.45$2.00▼$16.10$11.72M1.185,025 shsN/APDSBPDS Biotechnology$0.77-1.7%$1.03$0.51▼$1.55$43.20M1.59461,816 shs305,277 shsSCYXSCYNEXIS$4.38-4.2%$5.08$3.68▼$10.48$43.49M1.1187,363 shs111,468 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed0.00%+0.56%+46.31%-6.79%-46.23%FNCHFinch Therapeutics Group0.00%0.00%0.00%-8.75%-43.85%PDSBPDS Biotechnology0.00%-9.28%-30.90%-28.34%-41.37%SCYXSCYNEXIS0.00%-1.13%+3.30%-45.25%-21.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$3.57-4.5%$3.36$2.13▼$13.13$48.29M-0.6816.89 million shs250,204 shsFNCHFinch Therapeutics Group$7.30$7.45$2.00▼$16.10$11.72M1.185,025 shsN/APDSBPDS Biotechnology$0.77-1.7%$1.03$0.51▼$1.55$43.20M1.59461,816 shs305,277 shsSCYXSCYNEXIS$4.38-4.2%$5.08$3.68▼$10.48$43.49M1.1187,363 shs111,468 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed0.00%+0.56%+46.31%-6.79%-46.23%FNCHFinch Therapeutics Group0.00%0.00%0.00%-8.75%-43.85%PDSBPDS Biotechnology0.00%-9.28%-30.90%-28.34%-41.37%SCYXSCYNEXIS0.00%-1.13%+3.30%-45.25%-21.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVOCervoMed 2.63Moderate Buy$22.60533.05% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/APDSBPDS Biotechnology 2.33Hold$9.001,062.94% UpsideSCYXSCYNEXIS 2.00Hold$24.00447.95% UpsideCurrent Analyst Ratings BreakdownLatest FNCH, SCYX, CRVO, and PDSB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026CRVOCervoMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/26/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/12/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026CRVOCervoMed Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.004/23/2026CRVOCervoMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/22/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.004/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRVOCervoMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.00(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVOCervoMed$4.01M12.05N/AN/A$1.97 per share1.81FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.18 per shareN/ASCYXSCYNEXIS$20.60M2.11N/AN/A$9.07 per share0.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVOCervoMed-$26.97M-$3.28N/AN/AN/A-672.80%-136.08%-112.62%8/14/2026 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/APDSBPDS Biotechnology-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)SCYXSCYNEXIS-$8.61M-$3.84N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)Latest FNCH, SCYX, CRVO, and PDSB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026CRVOCervoMed-$0.90-$0.86+$0.04-$0.86$0.07 millionN/A5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15-$0.13+$0.02-$0.13N/AN/A5/11/2026Q1 2026SCYXSCYNEXIS-$0.10-$0.42-$0.32-$3.36$0.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVOCervoMedN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVOCervoMedN/A3.363.36FNCHFinch Therapeutics GroupN/A3.873.87PDSBPDS Biotechnology2.732.262.26SCYXSCYNEXISN/A3.943.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVOCervoMed25.15%FNCHFinch Therapeutics Group21.77%PDSBPDS Biotechnology26.84%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipCRVOCervoMed35.80%FNCHFinch Therapeutics Group44.90%PDSBPDS Biotechnology8.40%SCYXSCYNEXIS4.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVOCervoMed413.53 million8.68 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataPDSBPDS Biotechnology2055.82 million51.13 millionOptionableSCYXSCYNEXIS609.93 million9.52 millionOptionableFNCH, SCYX, CRVO, and PDSB HeadlinesRecent News About These CompaniesSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 30, 2026 | globenewswire.comSCYNEXIS Shareholders Approve Governance and Equity Plan ChangesJune 26, 2026 | tipranks.comSCYNEXIS Inc.June 24, 2026 | marketwatch.comSCYNEXIS Announces One-for-Eight Reverse Stock SplitMay 22, 2026 | globenewswire.comSCYNEXIS (SCYX) price target increased by 20.73% to 4.28May 14, 2026 | msn.comSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 11, 2026 | globenewswire.comSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSCYNEXIS Raises $40 Million in Strategic Private PlacementApril 19, 2026 | theglobeandmail.comSCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics TranscriptMarch 31, 2026 | seekingalpha.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...March 31, 2026 | markets.businessinsider.comWhy did SCYX stock jump 10% in pre-market today?March 31, 2026 | msn.comPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionMarch 31, 2026 | businesswire.comSCYNEXIS Announces $40.0 Million Private PlacementMarch 31, 2026 | globenewswire.comSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)March 31, 2026 | globenewswire.comSCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal TherapyMarch 12, 2026 | insidermonkey.comScynexis: Q4 Earnings SnapshotMarch 4, 2026 | wiltonbulletin.comWSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 4, 2026 | globenewswire.comSCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA DesignationsFebruary 26, 2026 | quiverquant.comQSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247February 26, 2026 | globenewswire.comCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsFebruary 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFNCH, SCYX, CRVO, and PDSB Company DescriptionsCervoMed NASDAQ:CRVO$3.57 -0.17 (-4.55%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$3.64 +0.07 (+1.96%) As of 07/10/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Finch Therapeutics Group NASDAQ:FNCH$7.30 0.00 (0.00%) As of 07/10/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.PDS Biotechnology NASDAQ:PDSB$0.77 -0.01 (-1.69%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$0.78 +0.00 (+0.14%) As of 07/10/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.SCYNEXIS NASDAQ:SCYX$4.38 -0.19 (-4.16%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$4.40 +0.02 (+0.53%) As of 07/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
